CONTEXT: Given the higher risk of AIDS-defining malignancies that include Kaposi sarcoma (KS), certain non-Hodgkin lymphomas (NHLs), and cervical cancer in persons with human immunodeficiency virus (HIV) infection, the HIV epidemic has likely contributed to the overall numbers of these cancers in the United States. OBJECTIVE: To quantify the proportions of KS, AIDS-defining NHLs, and cervical cancer in the United States that occurred among persons with AIDS from 1980 to 2007. DESIGN, SETTING, AND PARTICIPANTS: The HIV/AIDS Cancer Match Study (1980-2007) linked data from 16 US HIV/AIDS and cancer registries to identify cases with and without AIDS for KS, AIDS-defining NHLs (ie, diffuse large B-cell lymphoma [DLBCL], Burkitt lymphoma [BL], and central nervous system [CNS] lymphoma), and cervical cancer. Using linked data, we derived cancer rates for persons with and without AIDS. To estimate national counts, the rates were applied to national AIDS surveillance and US Census data. MAIN OUTCOME MEASURE: Proportion of AIDS-defining malignancies in the United States occurring in persons with AIDS. RESULTS: In the United States, an estimated 81.6% (95% confidence interval [CI], 81.2%-81.9%) of 83,252 KS cases, 6.0% (95% CI, 5.8%-6.1%) of 351,618 DLBCL cases, 19.9% (95% CI, 18.1%-21.7%) of 17,307 BL cases, 27.1% (95% CI, 26.1%-28.1%) of 27,265 CNS lymphoma cases, and 0.42% (95% CI, 0.37%-0.47%) of 375,452 cervical cancer cases occurred among persons with AIDS during 1980-2007. The proportion of KS and AIDS-defining NHLs in persons with AIDS peaked in the early 1990s (1990-1995: KS, 90.5% [95% CI, 90.2%-90.8%]; DLBCL, 10.2% [95% CI, 9.9%-10.5%]; BL, 27.8% [95% CI, 25.0%-30.5%]; and CNS lymphoma, 48.3% [95% CI, 46.7%-49.8%]; all P < .001 [compared with 1980-1989]) and then declined (2001-2007: KS, 70.5% [95% CI, 68.1%-73.0%]; DLBCL, 4.7% [95% CI, 4.3%-5.2%]; BL, 21.5% [95% CI, 17.7%-25.4%]; and CNS lymphoma, 12.9% [95% CI, 10.5%-15.3%]; all P < .001 [compared with 1990-1995]). The proportion of cervical cancers in persons with AIDS increased over time (1980-1989: 0.11% [95% CI, 0.09%-0.13%]; 2001-2007: 0.71% [95% CI, 0.51%-0.91%]; P < .001). CONCLUSIONS: In the United States, the estimated proportions of AIDS-defining malignancies that occurred among persons with AIDS were substantial, particularly for KS and some NHLs. Except for cervical cancer, the proportions of AIDS-defining malignancies occurring among persons with AIDS peaked in the mid-1990s and then declined.
CONTEXT: Given the higher risk of AIDS-defining malignancies that include Kaposi sarcoma (KS), certain non-Hodgkin lymphomas (NHLs), and cervical cancer in persons with humanimmunodeficiency virus (HIV) infection, the HIV epidemic has likely contributed to the overall numbers of these cancers in the United States. OBJECTIVE: To quantify the proportions of KS, AIDS-defining NHLs, and cervical cancer in the United States that occurred among persons with AIDS from 1980 to 2007. DESIGN, SETTING, AND PARTICIPANTS: The HIV/AIDS Cancer Match Study (1980-2007) linked data from 16 US HIV/AIDS and cancer registries to identify cases with and without AIDS for KS, AIDS-defining NHLs (ie, diffuse large B-cell lymphoma [DLBCL], Burkitt lymphoma [BL], and central nervous system [CNS] lymphoma), and cervical cancer. Using linked data, we derived cancer rates for persons with and without AIDS. To estimate national counts, the rates were applied to national AIDS surveillance and US Census data. MAIN OUTCOME MEASURE: Proportion of AIDS-defining malignancies in the United States occurring in persons with AIDS. RESULTS: In the United States, an estimated 81.6% (95% confidence interval [CI], 81.2%-81.9%) of 83,252 KS cases, 6.0% (95% CI, 5.8%-6.1%) of 351,618 DLBCL cases, 19.9% (95% CI, 18.1%-21.7%) of 17,307 BL cases, 27.1% (95% CI, 26.1%-28.1%) of 27,265 CNS lymphoma cases, and 0.42% (95% CI, 0.37%-0.47%) of 375,452 cervical cancer cases occurred among persons with AIDS during 1980-2007. The proportion of KS and AIDS-defining NHLs in persons with AIDS peaked in the early 1990s (1990-1995: KS, 90.5% [95% CI, 90.2%-90.8%]; DLBCL, 10.2% [95% CI, 9.9%-10.5%]; BL, 27.8% [95% CI, 25.0%-30.5%]; and CNS lymphoma, 48.3% [95% CI, 46.7%-49.8%]; all P < .001 [compared with 1980-1989]) and then declined (2001-2007: KS, 70.5% [95% CI, 68.1%-73.0%]; DLBCL, 4.7% [95% CI, 4.3%-5.2%]; BL, 21.5% [95% CI, 17.7%-25.4%]; and CNS lymphoma, 12.9% [95% CI, 10.5%-15.3%]; all P < .001 [compared with 1990-1995]). The proportion of cervical cancers in persons with AIDS increased over time (1980-1989: 0.11% [95% CI, 0.09%-0.13%]; 2001-2007: 0.71% [95% CI, 0.51%-0.91%]; P < .001). CONCLUSIONS: In the United States, the estimated proportions of AIDS-defining malignancies that occurred among persons with AIDS were substantial, particularly for KS and some NHLs. Except for cervical cancer, the proportions of AIDS-defining malignancies occurring among persons with AIDS peaked in the mid-1990s and then declined.
Authors: Eric A Engels; Ruth M Pfeiffer; James J Goedert; Phillip Virgo; Timothy S McNeel; Steven M Scoppa; Robert J Biggar Journal: AIDS Date: 2006-08-01 Impact factor: 4.177
Authors: Kieron Dunleavy; Richard F Little; Stefania Pittaluga; Nicole Grant; Alan S Wayne; Jorge A Carrasquillo; Seth M Steinberg; Robert Yarchoan; Elaine S Jaffe; Wyndham H Wilson Journal: Blood Date: 2010-02-03 Impact factor: 22.113
Authors: H Irene Hall; Ruiguang Song; Philip Rhodes; Joseph Prejean; Qian An; Lisa M Lee; John Karon; Ron Brookmeyer; Edward H Kaplan; Matthew T McKenna; Robert S Janssen Journal: JAMA Date: 2008-08-06 Impact factor: 56.272
Authors: L M Larocca; D Capello; A Rinelli; S Nori; A Antinori; A Gloghini; A Cingolani; A Migliazza; G Saglio; S Cammilleri-Broet; M Raphael; A Carbone; G Gaidano Journal: Blood Date: 1998-08-01 Impact factor: 22.113
Authors: Meredith S Shiels; Stephen R Cole; Scott Wegner; Haroutune Armenian; Joan S Chmiel; Anuradha Ganesan; Vincent C Marconi; Otoniel Martinez-Maza; Jeremy Martinson; Amy Weintrob; Lisa P Jacobson; Nancy F Crum-Cianflone Journal: J Acquir Immune Defic Syndr Date: 2008-08-01 Impact factor: 3.731
Authors: J J Goedert; T R Coté; P Virgo; S M Scoppa; D W Kingma; M H Gail; E S Jaffe; R J Biggar Journal: Lancet Date: 1998-06-20 Impact factor: 79.321
Authors: Hilary A Robbins; Ruth M Pfeiffer; Meredith S Shiels; Jianmin Li; H Irene Hall; Eric A Engels Journal: J Natl Cancer Inst Date: 2015-02-06 Impact factor: 13.506
Authors: Sanghyuk S Shin; Catherine L Carpenter; Maria L Ekstrand; Qiao Wang; Surbhi Grover; Nicola M Zetola; Kartik Yadav; Sanjeev Sinha; Adeline M Nyamathi Journal: Int J STD AIDS Date: 2019-02-27 Impact factor: 1.359
Authors: David J Riedel; Evelyn Ivy W Mwangi; Lori E Fantry; Carla Alexander; Mian B Hossain; C David Pauza; Robert R Redfield; Bruce L Gilliam Journal: AIDS Date: 2013-04-24 Impact factor: 4.177
Authors: Shalanda A Bynum; Lisa T Wigfall; Heather M Brandt; Carmen Hampton Julious; Saundra H Glover; James R Hébert Journal: AIDS Behav Date: 2016-09